ライフサイエンスコーパス: ALP

1 ALP activity in AVICs induced by TLR2 and TLR4 agonists

2 ALP activity in osteoblasts and TRAP activity in RAW264.

3 ALP activity was released from larval BBMVs prepared by

4 ALP analysis, on the contrary, detected similar amounts

5 ALP deserves routine monitoring, and the cause for an el

6 ALP is not a good proxy to assess Vtg levels in marine m

7 ALP response was defined as a >40% decrease from baselin

8 ALP was chosen as the biomarker due to its age-dependent

9 ALP-catalyzed hydrolysis of p-nitrophenyl phosphate (pNP

10 ALP/OXP-specific T cells reacted immediately to the addi

11 th CAD/MI (ALT OR 0.74, 95% CI 0.54 to 1.01, ALP OR 0.86, 95% CI 0.64 to 1.16 and GGT OR 1.08, 95% CI

12 omains in an ATN-1(alpha-actinin)- and ALP-1(ALP/Enigma)-dependent manner, where it contributes to th

13 ormal serum alkaline phosphatases (ALP) 74%; ALP above 1.5 times the upper limit of normal 13%; and c

14 h this novel sorting signal targets A(F-->A)-ALP into clathrin/AP-1 vesicles at the EE for retrieval

15 A(F-->A)-ALP was found to reach the PVC via early endosomes (EEs)

16 line phosphatase gene into the striatum (AAV.ALP).

17 were reached by week 12, no patient achieved ALP response or remission.

18 ease of both the substrate and/or the active ALP, in a biodegradable and low-cost material such as ze

19 (PTH), total alkaline phosphatase activity (ALP), calcium, and phosphorus, in minority infants and c

20 Allopurinol (ALP) hypersensitivity is a major cause of severe cutaneo

21 Genetically predicted ALT, ALP and GGT were not clearly associated with CAD/MI (ALT

22 AlfA, an ALP that pushes plasmids apart in Bacillus, relies on a

23 scein diphosphate as a signal reporter in an ALP-linked immunosorbent assay, the proposed system prov

24 s in groups 1 and 2, respectively, showed an ALP decline of more than 30% (P = 0.04).

25 s in groups 1 and 2, respectively, showed an ALP decline.

26 osorbent assays, the probe was coupled to an ALP-linked immunosorbent assay for the sensitive and sel

27 gnificantly and positively related with ANC, ALP, and ferritin, suggesting phthalates may be associat

28 SH3 domains in an ATN-1(alpha-actinin)- and ALP-1(ALP/Enigma)-dependent manner, where it contributes

29 The mean levels of plasma Hcy, ALT and ALP were significantly reduced in responders within 10 w

30 drolysis adenosine-5'-triphosphate (ATP) and ALP can hydrolysis pyrophosphate, both reactions produce

31 defined as a >40% decrease from baseline and ALP remission as ALP normalization (if baseline ALP 1.67

32 d TLR4 in AVICs reduced BMP-2 expression and ALP activity to PVIC levels.

33 and GGT levels and between the ABO locus and ALP levels.

34 One common feature of the PKA and ALP catalyzing process is that PKA can hydrolysis adenos

35 s tool has the potential to simplify PKA and ALP clinical measurement, thereby improving diagnostics

36 The detection limit for PKA and ALP were much lower than existing assays.

37 le of detecting the activity of both PKA and ALP.

38 the activity and inhibition of both PKA and ALP.

39 PSA and ALP were measured before each treatment cycle and 4 wk a

40 Combined elevations of PTH and ALP occurred in only 2.5% of children.

41 % of subjects had elevations of both PTH and ALP.

42 stanniocalcin 1 (STC1) but not of RUNX2 and ALP in DFCs.

43 dition, we provide evidence that the UPS and ALP might be functionally connected such that impairment

44 Considering any ALP decline as a response, no patient with increasing AL

45 decrease from baseline and ALP remission as ALP normalization (if baseline ALP 1.67x-2.8x ULN) or <1

46 ygotic twin males) were established to assay ALP activity, in vitro mineralization, and gene expressi

47 Mutations that affect the Z-disk-associated ALP-Enigma proteins have been linked to human muscular a

48 0.57, 0.83) for abnormal levels of ALT, AST, ALP, and GGT, respectively.

49 liver enzymes and continuous levels of AST, ALP, and GGT.

50 elopment by upregulating the levels of ATF4, ALP and RUNX2, and it stimulated angiogenesis of endothe

51 detection was performed after adding avidin-ALP to perform avidin-biotin reaction; the signal was ge

52 t decreased serum CTX levels and increased b-ALP levels.

53 Levels of serum bone alkaline phosphatase (B-ALP) and myeloperoxidase (MPO) activity in gingival tiss

54 nd IL-10, serum bone alkaline phosphatase (B-ALP) and tartrate-resistant acid phosphatase 5b (TRAP-5b

55 um, phosphorus, bone alkaline phosphatase (b-ALP), and terminal C telopeptide of collagen Type I (CTX

56 affect gingival IL-1beta and IL-10, serum B-ALP and TRAP-5b levels, or alveolar bone compared with c

57 ound in gingival IL-1beta and IL-10, serum B-ALP and TRAP-5b, and calcium and alveolar bone levels be

58 day 18, the animals were sacrificed, serum B-ALP, TRAP-5b, and calcium levels were measured, gingiva

59 oups treated with antioxidant according to B-ALP, MPO, RANKL, and BDI values (P <0.05).

60 ical characterization of the nanoceria-based ALP activity assay was established using a 1-naphthyl ph

61 mol/L); 13 of 20 (65%) patients had baseline ALP >3x ULN.

62 P 1.67x-2.8x ULN) or <1.67x ULN (if baseline ALP >2.8x ULN).

63 remission as ALP normalization (if baseline ALP 1.67x-2.8x ULN) or <1.67x ULN (if baseline ALP >2.8x

64 Because ALP is widely used in enzyme-linked immunosorbent assays

65 quacy of the procedure should be done before ALP is further assumed as a proxy of Vtg in other bivalv

66 is much data supporting differences between ALP families, there is little data regarding conservatio

67 retinopathy and in the former group between ALP treated and nontreated patients.

68 EILPs as an intermediate progenitor between ALPs and ILCps.

69 % confidence interval (CI) 1.62 to 5.52) but ALP OR 0.92 (95% CI 0.71 to 1.19) and GGT OR 0.88 (95% C

70 o form nanofibrils upon dephosphorylation by ALP, but CES-catalyzed cleavage of the ester bond on the

71 The ensuing T cell responses elicited by ALP or OXP were not limited to particular TCR Vbeta repe

72 cells from patients with MM, as measured by ALP activity at d 14 and Alizarin Red staining at d 21 (

73 herapy, did not otherwise appreciably change ALP and overt proof-of-concept was not established as pe

74 tinct from actin and the other characterized ALPs.

75 attachment or function, although circulating ALP activity was correlated significantly with incisor c

76 t differentiation markers, including COL1A1, ALP, and OC, in osteoblasts and PDL cells cultured on EM

77 while the two cell lines exhibit comparable ALP activities.

78 substrates and enzyme labels of conventional ALP assays.

79 UDCA administration significantly decreased ALP and sMet levels, and reduced relative liver weight.

80 For the first time, we were able to detect ALP at a concentration of approximately 4 x 10(-15) M or

81 Elevated ALP at 1 year, affecting 30% of patients, predicted both

82 ne monitoring, and the cause for an elevated ALP should be sought.

83 t with developmental delay, ID, and elevated ALP, we identified compound-heterozygous variants c.439d

84 steogenic transcription factors and enhanced ALP activity.

85 Finally, ALP maturation kinetics in vac8Delta and vac17Delta cell

86 The detection limits were 15fM for ALP and 0.75mM for pNPP.

87 on limit at a signal-to-noise ratio of 3 for ALP was estimated to be 0.02 units/L (~6 pM; 1 ng/mL).

88 tform and has demonstrated functionality for ALP detection in human serum.

89 n to design a turn-on fluorescence probe for ALP sensing.

90 doplasmic reticulum (ER) export receptor for ALP; and AP-3 subunit genes.

91 sion level of early osteogenic marker genes, ALP, Runx2, and type I collagen, which play a critical r

92 ccurrence of biliary sludge and lowered GGT, ALP, and ALT.

93 Maximum levels of GGT, ALP, and ALT were lower in the late PN group (P < 0.01).

94 Thirty-seven patients had a high ALP level (19 from group 1 and 18 from group 2).

95 P and BMP2 demonstrated significantly higher ALP and mineralization activity (P <0.05).

96 Of these, histology, ALP, and TE came out as the most promising.

97 though associated with a modest decrease in ALP after 28 weeks of therapy, did not otherwise appreci

98 ssue formation with significant increases in ALP and DMP1 staining in vivo, whereas DPSC/E106Q cells

99 nd decreases in cell number and increases in ALP and local factors typical of MG63 cells grown on SLA

100 ts given OCA had at least a 20% reduction in ALP compared with 8% (3 of 37) of patients given placebo

101 Silencing MGP by siRNA resulted in ALP activity that was increased by 197% +/- 8.4% (P </=

102 sphate) that could previously not be used in ALP assays can be conveniently colorimetrically detected

103 protein expression of bone markers including ALP, Cbfa-1, and periostin.

104 ne as a response, no patient with increasing ALP showed a PSA response (P = 0.036).

105 the Id2-mediated inhibition of Cbfa1-induced ALP activity and OCL production.

106 he fact that mutant alpha-synucleins inhibit ALP functioning by tightly binding to the receptor on th

107 milarly, SSRIs (except citalopram) inhibited ALP and bone mineralization by OB but only at 30 mumol/L

108 At higher doses of the inhibitors, ALP levels were attenuated, but dexamethasone-induced bi

109 ad applications in sensing schemes involving ALP.

110 oid progenitors and, unexpectedly, Irf8(-/-) ALPs produced more neutrophils in vivo than their wild-t

111 enching of BODIPY-ATP can be paired with its ALP-mediated dephosphorylation to design a turn-on fluor

112 A detection limit of 0.04 U/L ALP with a linear range up to 2U/L was obtained with asc

113 and osteocalcin (OCL) gene, leading to less ALP activity and osteocalcin (OCL) production.

114 that express approximately 15-20 times lower ALP activity compared to SaOs2) not being affected at co

115 reased activity of the calcification marker, ALP, in glaucomatous trabecular meshworks might be indic

116 ally significant relative reductions in mean ALP from baseline to the end of the study (P < .0001 all

117 BPS804 treatment increased mean ALP and bone-specific ALP enzymatic activity between day

118 However, at BMP2 concentrations >10 ng/mL, ALP, in vitro mineralization, and osteonectin were downr

119 Trabecular meshwork tissue showed moderate ALP activity at 13 days postinjection.

120 of the control specimens was 7.3 +/- 1.6 ng ALP/microg DNA (n = 4), whereas that of the glaucomatous

121 the glaucomatous tissue was 37.0 +/- 10.7 ng ALP/microg genomic DNA (n = 5; P </= 0.04).

122 Only 1 in 6 patients with AMAs and normal ALP will develop PBC after 5 years.

123 Among the patients with normal ALP and no evidence of cirrhosis, the 5-year incidence r

124 The normalized ALP of the control specimens was 7.3 +/- 1.6 ng ALP/micr

125 ds, adaptive L(infinity)-norm penalized NSC (ALP-NSC) and adaptive hierarchically penalized NSC (AHP-

126 for human health, the mechanism of action of ALP-Enigma proteins is largely unknown.

127 cles as redox active catalytic amplifiers of ALP signals.

128 present a molecular and genetic analysis of ALP-Enigma function in C. elegans.

129 elastography (TE); histology; combination of ALP+histology; and bilirubin.

130 ancement was related to the concentration of ALP.

131 Area under the curve of ALP in predicting graft loss from rejection was 0.81 (95

132 ers a straightforward and rapid detection of ALP activity with the enzyme present in the nanomolar co

133 hold a potential application in diagnosis of ALP-related diseases or evaluation of ALP functions in b

134 L required by legislation, (2) estimation of ALP in saliva and (3) chlorpyrifos control in commercial

135 sis of ALP-related diseases or evaluation of ALP functions in biological systems.

136 and resistant (58%) to butyrate induction of ALP activity.

137 The primary outcome was change in level of ALP from baseline (day 0) until the end of the study (da

138 gradable Dex-peptides had elevated levels of ALP activity and calcium deposition, whereas no elevated

139 ors exhibited significantly higher levels of ALP activity than their matched counterparts with normal

140 In the extension study, levels of ALP continued to decrease to a mean level of 202 +/- 11

141 Levels of ALP decreased 21%-25% on average from baseline in the OC

142 r evaluation and the physiological levels of ALP in healthy people, the applicability of this assay i

143 10 to 50 mg, significantly reduced levels of ALP, gamma-glutamyl transpeptidase, and alanine aminotra

144 eased relative liver weight, serum levels of ALP, sMet, and loss of intracellular glycogen.

145 anchored and that the proper localization of ALP-1 at dense bodies is dependent on alpha-actinin.

146 The immune mechanism of ALP-induced severe cutaneous adverse reactions is poorly

147 susceptible to pharmacological modulation of ALP function.

148 t that aggregation-dependent perturbation of ALP function is a relevant pathogenic mechanism for AD-A

149 upon exposure to the hydrolytic products of ALP.

150 st has been shown in identifying the role of ALP in neurodegeneration.

151 This probe was used for the screening of ALP inhibitors, including Na3VO4, imidazole, and arginin

152 The stability of ALP in serum allows for the differentiation between old

153 a2 significantly induced the upregulation of ALP activity in two trabecular meshwork primary cell lin

154 Using uncompetitive inhibitors of ALPs and fluorescent D-tetrapeptides, we delineate that

155 he cancer cell lines express higher level of ALPs are more susceptible to inhibition by the phosphory

156 i strains use their different repertoires of ALPs to create diversity in their metabolic niches, by a

157 inkage between the dysfunction of the UPS or ALP and the occurrence of this disorder.

158 pulation sampled in the American Life Panel (ALP).

159 The autophagy-lysosomal pathway (ALP) is involved in the degradation of long-lived protei

160 em (UPS) or the autophagy-lysosomal pathway (ALP).

161 system (UPS) and autophagy-lysosome pathway (ALP) are the two most important mechanisms that normally

162 s to explain the autophagy-lysosome pathway (ALP) dysfunction in cells from AD-ANCL patients.

163 ctivation of the autophagy-lysosome pathway (ALP) in a mammalian target of rapamycin (mTOR)-independe

164 Median percent ALP reduction from baseline to week 28 was 12.1%.

165 ALP) elevations were also common, persistent ALP elevations lasting up to 17.6 years were seen in 25%

166 , P = 0.007-0.03), and alkaline phosphatase (ALP) (HR 1.05, P < 0.001).

167 % women) and levels of alkaline phosphatase (ALP) 1.5- to 10-fold the upper limit of normal.

168 Elevated alkaline phosphatase (ALP) activities and calcium deposition levels were obser

169 ls exhibited increased alkaline phosphatase (ALP) activity and expression of osteogenic genes in vitr

170 observations of lower alkaline phosphatase (ALP) activity and higher expression of CD105, a stem cel

171 analogs for detecting alkaline phosphatase (ALP) activity and inhibition.

172 dependent reduction in alkaline phosphatase (ALP) activity and osteocalcin mRNA expression was observ

173 tedly, Wnt-1 inhibited alkaline phosphatase (ALP) activity and the formation of mineralized nodules i

174 5-fold decrease in the alkaline phosphatase (ALP) activity in comparison to cells treated with osteog

175 shwork (HTM) cells and alkaline phosphatase (ALP) activity in the angle tissue.

176 RP gradually increased alkaline phosphatase (ALP) activity in the cells in a dose-dependent manner.

177 y for the detection of alkaline phosphatase (ALP) activity is reported based on the surface reactivit

178 erentiation of DFCs by alkaline phosphatase (ALP) activity measurement, alizarin red staining, and el

179 s analyzed in terms of alkaline phosphatase (ALP) activity of KS483-4C3 mouse progenitor cells, and t

180 Alkaline phosphatase (ALP) activity was used as a marker of osteogenic differe

181 elated genes, elevated alkaline phosphatase (ALP) activity, and enhanced mineralization.

182 evidenced by increased alkaline phosphatase (ALP) activity, compared to the direct infusion of Dex in

183 nd biosensors based on alkaline phosphatase (ALP) activity/inhibition in the presence of phosphatase

184 ion as demonstrated by alkaline phosphatase (ALP) activity/staining as well as alizarin red S stainin

185 s had higher levels of alkaline phosphatase (ALP) and alpha-fetoprotein (AFP) and lower level of alan

186 days were assessed for alkaline phosphatase (ALP) and bone mineralization.

187 minotransferase (ALT), alkaline phosphatase (ALP) and gamma glutamyltransferase (GGT), on diabetes an

188 minotransferase (AST), alkaline phosphatase (ALP) and gamma-glutamytransferase (gamma-GT).

189 arious enzymes such as alkaline phosphatase (ALP) and horseradish peroxidise (HRP).

190 d transcription of the alkaline phosphatase (ALP) and osteocalcin (OCL) gene, leading to less ALP act

191 ' fragments of an anti-alkaline phosphatase (ALP) antibody to orient all the antigenic binding sites

192 otein kinase (PKA) and alkaline phosphatase (ALP) are clinically relevant enzymes for a number of dis

193 gonist Sclerostin, and alkaline phosphatase (ALP) are two additional targets of mir-204/211.

194 nylphosphate (pNPP) by alkaline phosphatase (ALP) bound on paramagnetic-beads was performed into a sm

195 Alkaline phosphatase (ALP) catalyzes the hydrolisis of sodium thiophosphate (T

196 Although transient alkaline phosphatase (ALP) elevations were also common, persistent ALP elevati

197 Calcification marker alkaline phosphatase (ALP) enzyme activity was assayed by fluorescence produce

198 the tissue-nonspecific alkaline phosphatase (ALP) enzyme.

199 nt export of secretory alkaline phosphatase (ALP) from the endoplasmic reticulum depends on the conse

200 tection sensitivity of alkaline phosphatase (ALP) in electrochemical assays by using nanoceria partic

201 ly can be triggered by alkaline phosphatase (ALP) in solution or in situ by the ALP produced by osteo

202 2), and three loci for alkaline phosphatase (ALP) levels (ALPL on chromosome 1, GPLD1 on chromosome 6

203 ent strategy to detect alkaline phosphatase (ALP) under physiological conditions has been developed.

204 f assay for the enzyme alkaline phosphatase (ALP) using PPi as the substrate is developed.

205 Alkaline phosphatase (ALP) was visualized in the vossicles to assess osteoblas

206 vacuolar maturation of alkaline phosphatase (ALP), a cargo of the AP-3 pathway.

207 showed elevated serum alkaline phosphatase (ALP), a GPI-anchored enzyme, in all three affected child

208 ntified, the levels of alkaline phosphatase (ALP), a marker commonly used in clinical diagnostics cor

209 Alkaline phosphatase (ALP), alpha2 and beta1 mRNA, but not alpha5, alpha v, be

210 des tissue nonspecific alkaline phosphatase (ALP), an enzyme that promotes mineralization by reducing

211 minotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transaminase (GGT) were measure

212 ly osteogenic markers, alkaline phosphatase (ALP), and osteoprotegerin (OPG) by hMSCs and transcripto

213 ence of high levels of alkaline phosphatase (ALP), and presence of the efflux transporter, P-glycopro

214 ific antigen (PSA) and alkaline phosphatase (ALP), as well as the correlation of PSA changes with the

215 minotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), or total bili

216 Expression of alkaline phosphatase (ALP), in vitro mineralization along with osteonectin exp

217 of homocysteine, ALT, alkaline phosphatase (ALP), lipid profile and liver ultrasonographic examinati

218 ranscription factor 2, alkaline phosphatase (ALP), osteocalcin (OC), and collagen1alpha1 (COL1A1), an

219 y was quantified using alkaline phosphatase (ALP), relative liver weight, and confirmed by histologic

220 of tissue non-specific alkaline phosphatase (ALP), resulting in increased pyrophosphate (PP(i)) and a

221 We discovered that alkaline phosphatase (ALP), the enzyme broadly used in enzyme-linked immuno-so

222 phosphate (1-NP), for alkaline phosphatase (ALP).

223 g disease progression: alkaline phosphatase (ALP); transient elastography (TE); histology; combinatio

224 ic acid therapy (i.e., alkaline phosphatase [ALP] >1.67x upper limit of normal [ULN] after >/=6 month

225 ic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.

226 bin) and inflammation (alkaline phosphatase [ALP], absolute neutrophil count [ANC], ferritin [adjuste

227 transpeptidase [GGT], alkaline phosphatase [ALP], twice weekly; n = 3,216) were quantified.

228 ers of liver function (alkaline phosphatase, ALP, and aspartate aminotransferase, AST) and total seru

229 ers 46%; normal serum alkaline phosphatases (ALP) 74%; ALP above 1.5 times the upper limit of normal

230 lesterases (CESs) and alkaline phosphatases (ALPs).

231 ells that overexpress alkaline phosphatases (ALPs).

232 Alkaline phosphatases (ALPs, EC 3.1.3.1) isolated from lepidopteran and diptera

233 indirect technique, alkali labile phosphate (ALP), that assumes that vitellogenin is the most abundan

234 indicated by increased alkaline phosphates (ALP) activity and calcium deposition.

235 A116T) mice featured 50% reduction in plasma ALP activity compared with wild-type controls.

236 s were identified that accumulated precursor ALP, many with established defects in vacuolar protein t

237 ed the mechanism by which Erv26p couples pro-ALP to the coat protein complex II (COPII) export machin

238 ee assays that monitor interactions with pro-ALP cargo and packaging into COPII vesicles.

239 ins of Erv26p inhibited interaction with pro-ALP, whereas mutations in the C-terminal tail sequence i

240 ips between EILPs, all-lymphoid progenitors (ALPs), and ILC precursors (ILCps).

241 differentiate into all lymphoid progenitors (ALPs).

242 The 101 adhesin-like proteins (ALPs) in the pan-genome (45 +/- 6 per strain) exhibit st

243 ea contain a variety of actin-like proteins (ALPs) that form filaments with surprisingly diverse arch

244 er cells by assembly of actin-like proteins (ALPs).

245 y (mouse-anti BoNT/E) followed by RalphaMIgG-ALP/AuNPs.

246 onalized with gold nanoparticles (RalphaMIgG-ALP/AuNPs).

247 i-mouse IgG-alkaline phosphatase (RalphaMIgG-ALP) functionalized with gold nanoparticles (RalphaMIgG-

248 e HLA-B*58:01 molecule for drug recognition, ALP-specific T cells also were restricted to other MHC c

249 Overexpression of MGP in HTM cells reduced ALP activity in a model of BMP2-induced osteogenesis.

250 PP-PDL cells exhibited significantly reduced ALP and mineralizing capacity, which were rescued by add

251 eolar development and function under reduced ALP, bringing attention to direct effects of HPP on alve

252 onation and fluorescence microscopy revealed ALP transport defects in yck3Delta cells.

253 of osteoblast marker genes, including Runx2, ALP, OC, BSP, OPG, and DMP-1, with concurrent upregulati

254 In real time (i.e. in about 1 s), ALP (Ascending Ladder Program) calculates the E-values f

255 to coordinately modulate Runx2, Sclerostin, ALP and Dlx5 proteins at levels appropriate for optimal

256 and suggests that divergent DNA-segregating ALPs with different assembly properties operate via diff

257 eatment increased mean ALP and bone-specific ALP enzymatic activity between days 2 and 29.

258 elegans provides an excellent model to study ALP-Enigma function.

259 Taken together, our data demonstrate that ALP-1 and alpha-actinin function together to stabilize a

260 analysis of alp-1 mutants demonstrates that ALP-1 functions to maintain actin filament organization

261 We show that ALP-1 and alpha-actinin colocalize at dense bodies where

262 notype of the alp-1 mutants, suggesting that ALP-1 and alpha-actinin function in the same cellular pr

263 The ALP-catalyzed hydrolysis of BODIPY-ATP resulted in the f

264 The ALP-catalyzed PPi hydrolysis would disable the complexat

265 le with increased alpha-synuclein burden the ALP is recruited.

266 gregated CSPalpha are degraded mainly by the ALP but this disease-causing mutation exhibits a faster

267 sphatase (ALP) in solution or in situ by the ALP produced by osteosarcoma cell line, SaOs2.

268 In Caenorhabditis elegans, the ALP-Enigma protein family is encoded by a single gene, a

269 arch have therefore focused on enhancing the ALP in neurodegenerative diseases.

270 -on mode provides a high selectivity for the ALP assay.

271 R code for the ALP-NSC and the AHP-NSC algorithms are available from au

272 nse to ALP is demonstrated to arise from the ALP catalyzed hydrolysis of PPi to phosphate (Pi).

273 did not show a significant reduction in the ALP activity.

274 Deficits in the ALP result in protein aggregation, the generation of tox

275 ents demonstrate signal amplification of the ALP activity assay by nanoceria for all three products,

276 We review the regulation of the ALP and TFEB and their impact on neurodegenerative disea

277 anges after interaction with products of the ALP catalyzed reaction, resulting in charge transfer com

278 his topic and discuss the unique role of the ALP in this neurogenerative disorder and the putative th

279 pports the assumption that impairment of the ALP may be related to the development of Parkinson's dis

280 None of the ALP-associated SNPs were associated with other liver tes

281 ity enabled oxidation of the products of the ALP-catalyzed reaction.

282 y, the inhibition effect of phosphate on the ALP activity was also studied.

283 These results show evidence that the ALP method is not providing reliable information about V

284 ts provide a novel link between the UPS, the ALP, and alpha-synuclein pathology and may have importan

285 red the results with those obtained with the ALP method.

286 terize the interaction of nanoceria with the ALP-generated products.

287 d the putative therapeutic potential through ALP enhancement.

288 d requirement is bypassed by fusing Atg18 to ALP, a vacuolar transmembrane protein, vac14Delta vacuol

289 TCR, we generated T cell lines that react to ALP or its metabolite oxypurinol (OXP) from HLA-B*58:01(

290 ay solution; however, the signal response to ALP is demonstrated to arise from the ALP catalyzed hydr

291 The best understood ALP, ParM, has a core set of biochemical properties that

292 In agreement with this, ALN upregulated ALP activity considerably in vossicles.

293 PDL cells and osteoblasts upregulated ALP and in vitro mineralization in a dose-dependent mann

294 atically generated products of commonly used ALP substrates were detected at a screen printing electr

295 with a subsample of highly educated, wealthy ALP subjects as well as elite law school students and un

296 10(-15) M or at single-molecule levels when ALP was incubated with BCIP for 1 h in the Tris-HCl buff

297 cific interaction of analyte (antibody) with ALP-labeled antibody can be detected through formation o

298 The specific associations with ALP levels may point to genes for bone or intestinal dis

299 ate (FDP) and immuno-complex conjugated with ALP.

300 The PDR group treated with ALP had significantly lower subbasal nerves number compa